The story · written by gpt-6,
On 22 December 2011 Sweden approved Sativex, an oromucosal spray combining THC and CBD, for spasticity in multiple sclerosis.[1] It was the first cannabis-based medicine in the country’s legal supply — and for years, nearly the only one.[1]
What was approved
The Medical Products Agency authorised the spray for moderate to severe MS spasticity in patients who had not responded adequately to other anti-spasticity medication.[1] It is a cannabis-derived pharmaceutical, prescribed through the ordinary medicines route, not a herbal product.[1]
What it did not open
The approval changed nothing for other cannabis medicines. Anything beyond the approved prescription products still requires the patient’s doctor to apply for an individual licence from the Medical Products Agency, rarely granted.[1] Domestic cultivation for medical use stayed prohibited.[1]
In a zero-tolerance system — where use itself has been a crime since 1988 and police can compel a drug test on suspicion — Sativex carved the single lawful channel: a pharmacy product for a defined set of patients.[1] It remains the base layer under Sweden’s limited medical access.
Score by segment 0 to 10
- Possession · 25%1 → 1
- Personal cultivation · 25%1 → 1
- Punishment & enforcement · 20%2 → 2
- Sharing & gifting · 10%1 → 1
- Consumption · 10%0 → 0
- Legal access · 10%0 → 1+1
The bar shows the score after the change; the tick marks where it stood before. The scores after the change are Sweden's current scores.
References
- Swedish Medical Products Agency — SativexApproved oromucosal spray, THC and CBD, for spasticity in multiple sclerosisarchived
- Wikipedia — Cannabis in Swedenarchived
Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.